无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

產(chǎn)品訂購(gòu)信息：
英文名稱(chēng)  Anti-OPGL/RANKL/ODF 

中文名稱(chēng)   骨保護(hù)蛋白配體抗體(破骨細(xì)胞分化因子)說(shuō)明書(shū) 

別    名  CD254; hRANKL2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa B ligand; sOdf; SOFA; TNF related activation induced cytokine; TNFSF 11; TNFSF11; TRANCE; Tumor necrosis factor ligand superfamily member 11; Osteoprotegerin Ligand; TNF11_HUMAN.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg 0.2ml/200μg

抗體來(lái)源   Rabbit

克隆類(lèi)型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog 

產(chǎn)品類(lèi)型   一抗  

研究領(lǐng)域     細(xì)胞生物 免疫學(xué) 發(fā)育生物學(xué)

蛋白分子量  predicted molecular weight: 35kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human OPGL C-terminus 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

骨保護(hù)蛋白配體抗體(破骨細(xì)胞分化因子)說(shuō)明書(shū) 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.

Function : Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.

Subcellular Location : Cytoplasm; Secreted and Cell membrane.

Tissue Specificity : Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.

Post-translational modifications : The soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17.

DISEASE : Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.

Similarity : Belongs to the tumor necrosis factor family.

Database links : UniProtKB/Swiss-Prot: O14788.1

Entrez Gene: 8600 Human

Entrez Gene: 21943 Mouse

Omim: 602642 Human

SwissProt: O14788 Human

SwissProt: O35235 Mouse

Unigene: 333791 Human

Unigene: 249221 Mouse

OPGL骨保護(hù)蛋白配體又稱(chēng)骨保護(hù)素配體(破骨細(xì)胞發(fā)育刺激因子)。屬TNF-a家族。

OPGL促進(jìn)破骨細(xì)胞的分化和活性,而OPG抑制這些過(guò)程。細(xì)胞影響骨髓中這兩種蛋白的生理平衡，是發(fā)生溶骨性的根本所在。

HIF-1Alpha (Hypoxia-inducible factor -1Alpha) 缺氧誘導(dǎo)因子1α (抗原)Multi-class antibodies規(guī)格： 0.5mg

Anti-CD166/ALCAM/MEMD 活化白細(xì)胞粘附分子抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh PAR3 蛋白酶激活受體3抗體 規(guī)格 0.2ml

TREM2 Kit Human 人 TREM-2 / TREM2 ELISA配對(duì)抗體 ELISA

phospho-TPH (Ser260) 英文名稱(chēng)： 磷酸化色酸羥化酶抗體 0.1ml

NT5C2 英文名稱(chēng)： 胞漿-5′-核苷酸酶-Ⅱ抗體 0.1ml

Anti-CD166/ALCAM/MEMD 活化白細(xì)胞粘附分子抗體Multi-class antibodies規(guī)格： 0.2ml

HHV8/ORF K2/vIL-6(Human herpesvirus 8) 人類(lèi)病毒8抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-CD163/M130 CD163抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh PAR3 型蛋白激酶C特定相互作用蛋白抗體 規(guī)格 0.1ml

NOV Kit Human 人 CCN3 / NOV / IGFBP9 ELISA配對(duì)抗體 ELISA

TPA 英文名稱(chēng)： 組織型纖溶酶原激活劑抗體 0.1ml

CD86 英文名稱(chēng)： CD86抗體 0.1ml

Anti-CD163/M130 CD163抗體Multi-class antibodies規(guī)格： 0.2ml

NN-T4 ELISA Kit 大鼠新生甲狀腺素Multi-class antibodies規(guī)格： 48T

Anti-ATPase Na+/K+protein/FITC 熒光素標(biāo)記ATP酶通道蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh F-Actin 纖維狀肌動(dòng)蛋白抗體 規(guī)格 0.1ml

sCD30(Mouse soluble cluster of differentiation 30) Elisa Kit 小鼠可溶性CD30 96T

music Acetylcholine Receptor 1 英文名稱(chēng)： 毒蕈堿型乙酰膽堿受體M1抗體 0.1ml

Gamma-Adaptin 英文名稱(chēng)： 銜接蛋白γ/γ-Adaptin抗體 0.1ml

Anti-ATPase Na+/K+protein/FITC 熒光素標(biāo)記ATP酶通道蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml

TDGF1 Protein Rat 重組大鼠 Cripto / TDGF1 蛋白 (Fc 標(biāo)簽)

LS174T 人細(xì)胞

CD6 Others Mouse 小鼠 CD6 / TP120 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

MDA-MB-231人癌細(xì)胞 Human breast cancer cell line MDA-MB-231 L-15+10% Hyclone FBS

T739小鼠肺腺株;LA795

人羊膜細(xì)胞;WISH SGC-7901, 人胃腺癌細(xì)胞系 Human

CL-0303PATU8988(人*癌細(xì)胞)5×106cells/瓶×2

CD40LG Others Canine 狗 CD40L / CD154 / TNFSF5 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

人平滑肌細(xì)胞總RNAHBVSMC tDNA

山羊皮膚成纖維樣細(xì)胞;DG-S1 胚腎細(xì)胞，AAV-293細(xì)胞 HP615細(xì)胞，615小鼠瘤株

人干細(xì)胞因子單克隆抗體細(xì)胞株;AMS2(SCF3)

HA Others H5N1 甲型 H5N1 (A/Common magpie/Hong Kong/2256/2006) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

骨保護(hù)蛋白配體抗體(破骨細(xì)胞分化因子)說(shuō)明書(shū) TDGF1 Protein Rat 重組大鼠 Cripto / TDGF1 蛋白 (Fc 標(biāo)簽)

LS174T 人細(xì)胞

CD6 Others Mouse 小鼠 CD6 / TP120 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

MDA-MB-231人癌細(xì)胞 Human breast cancer cell line MDA-MB-231 L-15+10% Hyclone FBS

T739小鼠肺腺株;LA795

人羊膜細(xì)胞;WISH SGC-7901, 人胃腺癌細(xì)胞系 Human

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. 骨保護(hù)蛋白配體抗體(破骨細(xì)胞分化因子)說(shuō)明書(shū) 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；

3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴(lài)氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）骨保護(hù)蛋白配體抗體(破骨細(xì)胞分化因子)說(shuō)明書(shū) 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線(xiàn),計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。